184 related articles for article (PubMed ID: 11598248)
1. Selection of patients for resection of hepatic metastases: improved detection of extrahepatic disease with FDG pet.
Zealley IA; Skehan SJ; Rawlinson J; Coates G; Nahmias C; Somers S
Radiographics; 2001 Oct; 21 Spec No():S55-69. PubMed ID: 11598248
[TBL] [Abstract][Full Text] [Related]
2. Survival of patients evaluated by FDG-PET before hepatic resection for metastatic colorectal carcinoma: a prospective database study.
Strasberg SM; Dehdashti F; Siegel BA; Drebin JA; Linehan D
Ann Surg; 2001 Mar; 233(3):293-9. PubMed ID: 11224615
[TBL] [Abstract][Full Text] [Related]
3. The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases.
Wiering B; Krabbe PF; Jager GJ; Oyen WJ; Ruers TJ
Cancer; 2005 Dec; 104(12):2658-70. PubMed ID: 16315241
[TBL] [Abstract][Full Text] [Related]
4. Role of FDG-PET in the diagnosis and treatment of colorectal liver metastases.
Wiering B; Ruers TJ; Oyen WJ
Expert Rev Anticancer Ther; 2004 Aug; 4(4):607-13. PubMed ID: 15270664
[TBL] [Abstract][Full Text] [Related]
5. Utility of 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases.
Fong Y; Saldinger PF; Akhurst T; Macapinlac H; Yeung H; Finn RD; Cohen A; Kemeny N; Blumgart LH; Larson SM
Am J Surg; 1999 Oct; 178(4):282-7. PubMed ID: 10587184
[TBL] [Abstract][Full Text] [Related]
6. Unique site- and time-specific patterns of recurrence following resection of colorectal carcinoma hepatic metastases in patients staged by FDG-PET.
Finkelstein SE; Fernandez FG; Dehdashti F; Siegel BA; Hawkins WG; Linehan DC; Strasberg SM
J Hepatobiliary Pancreat Surg; 2008; 15(5):483-7. PubMed ID: 18836801
[TBL] [Abstract][Full Text] [Related]
7. FDG-PET for the pre-operative evaluation of colorectal liver metastases.
Arulampalam TH; Francis DL; Visvikis D; Taylor I; Ell PJ
Eur J Surg Oncol; 2004 Apr; 30(3):286-91. PubMed ID: 15028310
[TBL] [Abstract][Full Text] [Related]
8. The economic impact of 18FDG positron emission tomography in the surgical management of colorectal cancer with hepatic metastases.
Zubeldia JM; Bednarczyk EM; Baker JG; Nabi HA
Cancer Biother Radiopharm; 2005 Aug; 20(4):450-6. PubMed ID: 16114993
[TBL] [Abstract][Full Text] [Related]
9. Role of FDG-PET staging in selecting the optimum patient for hepatic resection of metastatic colorectal cancer.
Strasberg SM; Dehdashti F
J Surg Oncol; 2010 Dec; 102(8):955-9. PubMed ID: 21165998
[TBL] [Abstract][Full Text] [Related]
10. Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study.
Ruers TJ; Langenhoff BS; Neeleman N; Jager GJ; Strijk S; Wobbes T; Corstens FH; Oyen WJ
J Clin Oncol; 2002 Jan; 20(2):388-95. PubMed ID: 11786565
[TBL] [Abstract][Full Text] [Related]
11. FDG-PET improves the staging and selection of patients with recurrent colorectal cancer.
Lonneux M; Reffad AM; Detry R; Kartheuser A; Gigot JF; Pauwels S
Eur J Nucl Med Mol Imaging; 2002 Jul; 29(7):915-21. PubMed ID: 12111132
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of fluorine-18-deoxyglucose positron emission tomography in detecting tumor recurrence after local ablative therapy for liver metastases: a prospective study.
Langenhoff BS; Oyen WJ; Jager GJ; Strijk SP; Wobbes T; Corstens FH; Ruers TJ
J Clin Oncol; 2002 Nov; 20(22):4453-8. PubMed ID: 12431968
[TBL] [Abstract][Full Text] [Related]
13. The role of FDG-PET in the selection of patients with colorectal liver metastases.
Wiering B; Krabbe PF; Dekker HM; Oyen WJ; Ruers TJ
Ann Surg Oncol; 2007 Feb; 14(2):771-9. PubMed ID: 17086488
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of intraoperative sonography for revealing hepatic metastases from colorectal cancer in patients selected for surgery after undergoing FDG PET.
Rydzewski B; Dehdashti F; Gordon BA; Teefey SA; Strasberg SM; Siegel BA
AJR Am J Roentgenol; 2002 Feb; 178(2):353-8. PubMed ID: 11804891
[TBL] [Abstract][Full Text] [Related]
15. FDG positron emission tomography in the surveillance of hepatic tumors treated with radiofrequency ablation.
Anderson GS; Brinkmann F; Soulen MC; Alavi A; Zhuang H
Clin Nucl Med; 2003 Mar; 28(3):192-7. PubMed ID: 12592125
[TBL] [Abstract][Full Text] [Related]
16. The role of [18F]fluorodeoxyglucose positron emission tomography imaging in the evaluation of hepatocellular carcinoma.
Wudel LJ; Delbeke D; Morris D; Rice M; Washington MK; Shyr Y; Pinson CW; Chapman WC
Am Surg; 2003 Feb; 69(2):117-24; discussion 124-6. PubMed ID: 12641351
[TBL] [Abstract][Full Text] [Related]
17. The role of whole-body positron emission tomography with [18F]fluorodeoxyglucose in identifying operable colorectal cancer metastases to the liver.
Lai DT; Fulham M; Stephen MS; Chu KM; Solomon M; Thompson JF; Sheldon DM; Storey DW
Arch Surg; 1996 Jul; 131(7):703-7. PubMed ID: 8678767
[TBL] [Abstract][Full Text] [Related]
18. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET).
Fernandez FG; Drebin JA; Linehan DC; Dehdashti F; Siegel BA; Strasberg SM
Ann Surg; 2004 Sep; 240(3):438-47; discussion 447-50. PubMed ID: 15319715
[TBL] [Abstract][Full Text] [Related]
19. PET and PET-CT for evaluation of colorectal carcinoma.
Delbeke D; Martin WH
Semin Nucl Med; 2004 Jul; 34(3):209-23. PubMed ID: 15202102
[TBL] [Abstract][Full Text] [Related]
20. FDG-PET for detecting local tumor recurrence of ablated liver metastases: a diagnostic meta-analysis.
Poulou LS; Ziakas PD; Ziogas DC; Doxani C; Xyla V; Vakrinos G; Voulgarelis M; Thanos L
Biomarkers; 2012 Sep; 17(6):532-8. PubMed ID: 22712479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
